Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 6
2011 53
2012 116
2013 133
2014 171
2015 135
2016 167
2017 190
2018 189
2019 75
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

1,044 results
Results by year
Filters applied: . Clear all
Page 1
Tocilizumab (Actemra)
Sheppard M, et al. Hum Vaccin Immunother 2017 - Review. PMID 28841363 Free PMC article.
Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned
Hedrich WD, et al. Clin Pharmacokinet 2018 - Review. PMID 29188435 Free PMC article.
These conjugates combine the target specificity of monoclonal antibodies with the anti-cancer activity of small-molecule therapeutics. ...
These conjugates combine the target specificity of monoclonal antibodies with the anti-cancer activity of small-molecule therapeutics …
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Mahlangu J, et al. N Engl J Med 2018 - Clinical Trial. PMID 30157389 Free article.
There were no thrombotic or thrombotic microangiopathy events, development of antidrug antibodies, or new development of factor VIII inhibitors. ...
There were no thrombotic or thrombotic microangiopathy events, development of antidrug antibodies, or new development of factor VIII …
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial
Jankovic J, et al. JAMA Neurol 2018 - Clinical Trial. PMID 29913017 Free PMC article.
No antidrug antibodies were detected. Serum PRX002 levels increased in an approximately dose-proportional manner; mean terminal elimination half-life was similar across all doses (10.2 days). ...
No antidrug antibodies were detected. Serum PRX002 levels increased in an approximately dose-proportional manner; mean terminal elimi …
Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis
Ogungbenro K, et al. Clin Pharmacol Ther 2018 - Review. PMID 28913853
Pembrolizumab and nivolumab are highly selective anti-programmed cell death 1 (PD-1) antibodies approved for the treatment of advanced malignancies. Variable exposure and significant wastage have been associated with body size dosing of monoclonal antibodies (mAbs). The following dosing strategies were evaluated using simulations: body weight, dose banding, fixed dose, and pharmacokinetic (PK)-based methods. ...
Pembrolizumab and nivolumab are highly selective anti-programmed cell death 1 (PD-1) antibodies approved for the treatment of advance …
1,044 results
Jump to page
Feedback